Las Vegas NV / May 20, 2015 / (VRCI-OTCQB) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.
Mr. Schauer is a seasoned international banker, entrepreneur and investor with over four decades of business experience. He was educated in Germany, followed by a 15 year career with Deutsche Bank. Based in Hong Kong as Regional Treasurer he was responsible for asset and liability and risk management, and all money market and foreign exchange trading operations for Deutsche Banks Asia Pacific subsidiary network in 13 countries. He built up similar regional treasury capabilities for Amsterdam-Rotterdam Bank and Continental Illinois National Bank based in Hong Kong and Japan for another 5 years. From New Zealand Mr. Schauer now runs his own independent consulting business. This involves a wide range of international projects from corporate finance and early stage funding, to mergers and acquisitions and general corporate and management advisory services. Over the last dozen years he has been involved in a number of companies in the USA and Canada.
Mr. Schauer commented, I am excited of being part of the new Verde Science team. The company has an excellent opportunity to grow quickly and attain a strong position in the burgeoning medical marijuana pharma sector. I look forward to committing my expertise and experience in order to play my part in building Verde Science into a substantial and successful company.
Mr. Harp Sangha, Verdes CEO offered, Manfred Schauer is an important addition to the Verde team. His international banking and finance network and his vast experience and business acumen compliments and strengthens our ability to successfully execute the Verde business plan.
About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.
For further information please see our investor profile available on our website: www.verdescienceinc.com.
Harp Sangha, Chairman
Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.